Журнал "Почки" том 9, №3

Ñó÷àñíà ôàðìàêîòåðàï³ÿ / Modern Pharmacotherapy
Buchler M., Cochat P., Cosyns J.P., Mougenot B., Rider M.H., Antignac
C., Verellen-Dumoulin C., Pirson Y. A cluster of mutations in
the UMOD gene causes familial juvenile hyperuricemic nephropathy
with abnormal expression of uromodulin. J. Am. Soc. Nephrol. 2003.
14. 2883-2893.
35. Lusco M.A., Fogo A.B., Najafian B., Alpers C.E. AJKD Atlas of
Renal Pathology: Gouty Nephropathy. Am. J. Kidney Dis. 2017. 69. e5-e6.
36. Robins R.K. Potential Purine Antagonists. I. Synthesis of
Some 4, 6-Substituted Pyrazolo [3, 4-d] pyrimidines. J. Am. Chem.
Soc. 1956. 78. 784-790.
37. Pacher P., Nivorozhkin A., Szabo C. Therapeutic Effects of
Xanthine Oxidase Inhibitors: Renaissance Half a Century after the
Discovery of Allopurinol. Pharmacol. Rev. 2006. 58. 87-114.
38. Davies M.J., Trujillo A., Vijapurkar U., Damaraju C.V.,
Meininger G. Effect of canagliflozin on serum uric acid in patients with
type 2 diabetes mellitus. Diabetes Obes. Metab. 2015. 17.
39. Nakashima M., Uematsu T., Kosuge K., Kanamaru M. Pilot
study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist,
in healthy subjects. Eur. J. Clin. Pharmacol. 1992. 42. 333-335.
40. Desager J.P., Hulhoven R., Harvengt C. Uricosuric effect of fenofibrate
in healthy volunteers. J. Clin. Pharmacol. 1980. 20. 560-564.
41. Garg J.P., Chasan-Taber S., Blair A., Plone M., Bommer J.,
Raggi P., Chertow G.M. Effects of sevelamer and calcium-based phosphate
binders on uric acid concentrations in patients undergoing hemodialysis:
a randomized clinical trial. Arthritis Rheum. 2005. 52. 290-295.
42. Randall Jr. R.E. Urate Nephropathy following Chronic Ileostomy
Acidosis. Am. J. Nephrol. 2002. 22. 372-375.
43. Ngo T.C., Assimos D.G. Uric Acid nephrolithiasis: recent
progress and future directions. Rev. Urol. 2007. 9. 17-27.
44. Ben Salem C., Slim R., Fathallah N., Hmouda H. Drug-induced
hyperuricaemia and gout. Rheumatology. 2016. 56. 679-688.
45. Li L., Yang C., Zhao Y., Zeng X., Liu F., Fu P. Is hyperuricemia
an independent risk factor for new-onset chronic kidney disease?:
a systematic review and meta-analysis based on observational cohort
studies. BMC Nephrol. 2014. 15. 122.
46. Sturm G., Kollerits B., Neyer U., Ritz E., Kronenberg F.,
MMKD Study Group. Uric acid as a risk factor for progression of nondiabetic
chronic kidney disease? The Mild to Moderate Kidney Disease
(MMKD) Study. Exp. Gerontol. 2008. 43.
47. Madero M., Sarnak M.J., Wang X., Greene T., Beck G.G.J.,
Kusek J.W., Collins A.J., Levey A.S., Menon V. Uric acid and longterm
outcomes in CKD. Am. J. Kidney Dis. 2009. 53. 796-803.
48. Bose B., Badve S.V., Hiremath S.S., Boudville N., Brown F.G.,
Cass A., de Zoysa J.R., Fassett R.G., Faull R., Harris D.C., Hawley
C.M., Kanellis J., Palmer S.C., Perkovic V., Pascoe E.M., Rangan
G.K., Walker R.J., Walters G., Johnson D.W. Effects of uric
acid-lowering therapy on renal outcomes: a systematic review and
meta-analysis. Nephrol. Dial. Transplant. 2014. 29. 406-413.
49. Kanji T., Gandhi M., Clase C.M., Yang R. Urate lowering therapy
to improve renal outcomes in patients with chronic kidney disease:
systematic review and meta-analysis. BMC Nephrol. 2015. 16. 58.
50. Alvarez-Lario B., MacArron-Vicente J. Is there anything
good in uric acid? QJM. 2011. 104. 1015-1024.
51. Stetten D.J. Gout. Perspect. Biol. Med. 1959. 2. 185-196.
52. Montoye H.J., Mikkelsen W.M. Serum Uric Acid and
Achievement in High School. Arthritis Rheum. 1973. 16. 359-362.
53. Stetten D., Hearon J.Z. Intellectual level measured by army
classification battery and serum uric acid concentration. Science.
1959. 129. 1737.
54. Bloch S., Brackenridge C.J. Psychological, performance and
biochemical factors in medical students under examination stress.
J. Psychosom. Res. 1972. 16. 25-33.
55. Brooks G.W., Mueller E. Serum urate concentrations among
university professors; relation to drive, achievement, and leadership.
JAMA. 1966. 195. 415-418.
56. Members K.B. KDIGO 2012 Clinical Practice Guideline for
the Evaluation and Management of Chronic Kidney Disease. Kidney
Int. Suppl. 2013. 3. 5-14.
57. Feig D.I., Kang D.-H., Johnson R. Uric Acid and Cardiovascular
Risk. N. Engl. J. Med. 2008. 359. 1811-1821.
58. Culleton B., Larson M., Kannel W., Levy D. Serum uric acid
and risk for cardiovascular disease and death: the Framingham Heart
Study. Ann. Intern. Med. 1999. 131. 7-13.
59. Wheeler J.G., Juzwishin K.D.M., Eiriksdottir G., Gudnason
V., Danesh J. Serum Uric Acid and Coronary Heart Disease in
9,458 Incident Cases and 155,084 Controls: Prospective Study and
Meta-Analysis. PLoS Med. 2005. 2. e76.
60. Zhang T., Pope J. Cardiovascular effects of urate-lowering
therapies in patients with chronic gout: a systematic review and metaanalysis.
Rheumatol. 2017. 56. 1144-1153.
61. Gois P., Souza E. Pharmacotherapy for hyperuricemia in hypertensive
patients. Cochrane Database Syst. Rev. 2013. 1. CD008652.
62. Reuss-Borst M.A., Pape C.A., Tausche A.K. Hidden gout-
Ultrasound findings in patients with musculo-skeletal problems and
hyperuricemia. Springerplus. 2014. 3. 592.
63. Praga M., Alegre R., Hernandez E., Morales E., Dommguez-
Gil B., Carreno A., Andres A. Familial microscopic hematuria caused
by hypercalciuria and hyperuricosuria. Am. J. Kidney Dis. 2000. 35.
141-145.
64. Roncal-Jimenez C., Garcia-Trabanino R., Barregard L.,
Lanaspa M.A., Wesseling C., Harra T., Aragon A., Grases F., Jarquin
E.R., Gonzalez M.A., Weiss I., Glaser J., Sanchez-Lozada L.G.,
Johnson R.J. Heat Stress Nephropathy From Exercise-Induced Uric
Acid Crystalluria: A Perspective on Mesoamerican Nephropathy. Am.
J. Kidney Dis. 2016. 67. 20-30.
65. Fodor D., Nestorova R., Vlad V., Micu M. The place of musculoskeletal
ultrasonography in gout diagnosis. Med. Ultrason. 2014.
16. 336-344.
66. Loffler C., Sattler H., Loffler U., Kramer B., Bergner R. Size
matters: observations regarding the sonographic double contour sign in
different joint sizes in acute gouty arthritis. Z. Rheumatol. 2018. DОI:
10.1007/ s00393-018-0425-6.
67. Bhadu D., Das S., Wakhlu A., Dhakad U., Sharma M. Ultrasonographic
detection of double contour sign and hyperechoic aggregates
for diagnosis of gout: two sites examination is as good as six sites
examination. Int. J. Rheum. Dis. 2018. 21. 523-531.
68. Norkuviene E., Petraitis M., Apanaviciene I., Virviciute D., Baranauskaite
A. An optimal ultrasonographic diagnostic test for early gout:
A prospective controlled study. J. Int. Med. Res. 2017. 45. 1417-1429.
69. Reuss-Borst M., Pape C., Tausche A. Hidden gout- Ultrasound
findings in patients with musculo-skeletal problems and hyperuricemia.
Springerplus. 2014. 3. 592.
70. Anastasio P., Viggiano D., Zacchia M., Altobelli C., Capasso
G., De Santo N. Delay in Renal Hemodynamic Response to a Meat
Meal in Severe Obesity. Nephron. 2017. 136. 151-157.
Впервые опубликовано
в «Kidney Blood Press Res». 2018. № 43. Р. 606-615
Òîì 9, ¹ 3, 2020
www.mif-ua.com, http://kidneys.zaslavsky.com.ua 65